The lancet oncology
-
The lancet oncology · Jul 2022
Multicenter StudyOutcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe. ⋯ National Institute for Health and Care Research Imperial Biomedical Research Centre and the Cancer Treatment and Research Trust.
-
The lancet oncology · Jul 2022
Randomized Controlled TrialTumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis.
Tumour response heterogeneity to treatment is common across different foci in the same patient with cancer. However, the effect of heterogeneity on clinical outcome remains unclear. Here, we developed a quantitative assessment of tumour response heterogeneity and explored the correlation of tumour response heterogeneity with the clinical outcome. ⋯ National Natural Science Foundation of China (grant 82072565) and Bejing Xisike Clinical Oncology Research Foundation (grant Y-2019AZZD-0386).